Literature DB >> 27434219

D-dopachrome tautomerase is over-expressed in pancreatic ductal adenocarcinoma and acts cooperatively with macrophage migration inhibitory factor to promote cancer growth.

Dawei Guo1, Jinshuai Guo1, Junchao Yao1, Kun Jiang1, Jianhua Hu1, Bo Wang1, Haiyang Liu1, Lin Lin1, Wenyu Sun1, Xiaofeng Jiang1.   

Abstract

Previous studies have established the important role of MIF in the development of pancreatic ductal adenocarcinoma (PDAC) for both therapeutic and diagnostic perspectives, but little is known about the expression and function of D-dopachrome tautomerase (DDT), a functional homolog of MIF, in PDAC. In the present study, we demonstrated that DDT was over-expressed in PDAC tissues in a pattern correlated with MIF. In the pancreatic cancer cell lines, PANC-1, BXPC-3 and ASPC-1, both DDT and MIF were expressed and co-localized with each other in the endosomal compartments and plasma membrane. Knockdown of DDT and MIF in PANC-1 cells cooperatively inhibited ERK1/2 and AKT phosphorylation, increased p53 expression, and reduced cell proliferation, invasion and tumor formation. These effects were rescued by the re-expression of MIF or DDT, but not by the forced expression of the tautomerase-deficient mutants of DDT and MIF, P1G-DDT and P1G-MIF. Finally, we observed that 4-iodo-6-phenylpyrimidine (4-IPP), a covalent tautomerase inhibitor of both DDT and MIF, attenuated PANC-1 cell proliferation and colony formation in vitro and tumor growth in vivo. Thus, targeting the tautomerase sites of both MIF and DDT may offer more efficient therapeutic benefits to PDAC patients.
© 2016 UICC.

Entities:  

Keywords:  D-dopachrome tautomerase; invasion; macrophage migration inhibitory factor; pancreatic cancer; proliferation; tumor growth

Mesh:

Substances:

Year:  2016        PMID: 27434219     DOI: 10.1002/ijc.30278

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Structural Plasticity in the C-Terminal Region of Macrophage Migration Inhibitory Factor-2 Is Associated with an Induced Fit Mechanism for a Selective Inhibitor.

Authors:  Georgios Pantouris; Richard Bucala; Elias J Lolis
Journal:  Biochemistry       Date:  2018-06-12       Impact factor: 3.162

2.  Autophagic flux is essential for the downregulation of D-dopachrome tautomerase by atractylenolide I to ameliorate intestinal adenoma formation.

Authors:  Lu Li; Linlin Jing; Junjiang Wang; Wenjuan Xu; Xianling Gong; Yiye Zhao; Ye Ma; Xueqing Yao; Xuegang Sun
Journal:  J Cell Commun Signal       Date:  2018-01-24       Impact factor: 5.782

Review 3.  Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Joshua B Bilsborrow; Edward Doherty; Pathricia V Tilstam; Richard Bucala
Journal:  Expert Opin Ther Targets       Date:  2019-08-20       Impact factor: 6.902

Review 4.  Pathogenic role for macrophage migration inhibitory factor in glioblastoma and its targeting with specific inhibitors as novel tailored therapeutic approach.

Authors:  Katia Mangano; Emanuela Mazzon; Maria Sofia Basile; Roberto Di Marco; Placido Bramanti; Santa Mammana; Maria Cristina Petralia; Paolo Fagone; Ferdinando Nicoletti
Journal:  Oncotarget       Date:  2018-04-03

5.  "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

6.  D-dopachrome tautomerase from Japanese sea bass ( Lateolabrax japonicus) is a chemokine-like cytokine and functional homolog of macrophage migration inhibitory factor.

Authors:  Feng Xu; Ming-Yun Li; Jiong Chen
Journal:  Zool Res       Date:  2020-01-18

7.  D-dopachrome tautomerase activates COX2/PGE2 pathway of astrocytes to mediate inflammation following spinal cord injury.

Authors:  Huiyuan Ji; Yuxin Zhang; Chen Chen; Hui Li; Bingqiang He; Ting Yang; Chunshuai Sun; Huifei Hao; Xingyuan Zhang; Yingjie Wang; Yue Zhou; Zhenjie Zhu; Yuming Hu; Aihong Li; Aisong Guo; Yongjun Wang
Journal:  J Neuroinflammation       Date:  2021-06-11       Impact factor: 8.322

8.  Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma.

Authors:  Dong Wang; Ruizhi Wang; Anpei Huang; Zeng Fang; Kebing Wang; Meifang He; Jin-Tang Xia; Wen Li
Journal:  Oncol Rep       Date:  2018-09-12       Impact factor: 3.906

Review 9.  Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

Authors:  Eugenio Cavalli; Rosella Ciurleo; Maria Cristina Petralia; Paolo Fagone; Rita Bella; Katia Mangano; Ferdinando Nicoletti; Placido Bramanti; Maria Sofia Basile
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

10.  Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours.

Authors:  Devalingam Mahalingam; Manish R Patel; Jasgit C Sachdev; Lowell L Hart; Niels Halama; Ramesh K Ramanathan; John Sarantopoulos; Dirk Völkel; Ashraf Youssef; Floris A de Jong; Apostolia Maria Tsimberidou
Journal:  Br J Clin Pharmacol       Date:  2020-04-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.